This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

ADCETRIS is effective and provides long term overall survival in patients with a poor prognosis who relapse post-ASCT1-6

In the pivotal phase 2 trial, 33% of heavily pre-treated post-ASCT Hodgkin lymphoma patients achieved complete remission (n=34/102)

  • The estimated 5-year OS rate was 41% (95% CI: 31-51)

Study details

Objective response rate6
Objective response rate

Adapted from Adcetris Summary of Product Characteristics6

ADCETRIS delivers durable response and survival in CR patients1,2

  • In this heavily pre-treated population, 38% (13/34) of CR patients have achieved long-term disease control
  • Median PFS as per investigator analysis for CR patients has not been reached
  • Median OS for CR patients has not been reached

Study details

PFS by best response following treatment with ADCETRIS2

PFS by best response following treatment with ADCETRIS

Adapted from Chen et al. 2016

OS by best response following treatment with ADCETRIS2
OS by best response following treatment with ADCETRIS

Adapted from Chen et al. 2016

CR patients who achieved a durable remission with ADCETRIS may not require consolidative alloSCT for long term survival2

  • 15 patients remain in follow-up and in remission (13 CR and 2 PR) following a median observation time of 69.5 months (range 66.5–72.9)
  • 9 of 13 CR patients did not receive further treatment nor a consolidative alloSCT
  • Further cycles can be required to achieve a CR
  • In these 13 patients:
    • 7 achieved CR within 4 cycles
    • 6 achieved CR between 7-16 cycles

Time to achieve CR

CR patients who remain on study and in remission2
PFS – CR patients who remain on study and in remission (n=13)

Adapted from Chen et al. 2016

ADCETRIS is generally well tolerated. PN, generally resolves / improves in the majority of patients2,3

  • Grade ≥3 AEs in ≥5% of patients were 20% neutropenia, 8% sensory PN, 8% thrombocytopenia, 6% anaemia
  • Patients received a median of nine cycles (1-16) of brentuximab vedotin1
Reasons for treatment discontinuation
CR (n=34) PR (n=39)
Completed treatment n (%) 12 (35) 4 (10)
PD n (%) 4 (12) 23 (59)
AE n (%) 9 (26) 5 (13)
Investigator decision 7 (21) 4 (10)
Patient decision n (%) 2 (6) 3 (8)
Resolution of peripheral neuropathy
n=102
Patients experiencing PN, n (%) 56 (55%)
PN outcome, %
  • Complete resolution
  • Improvement
n=56
73% 14%
Ongoing PN Grade ≤2 at last follow-up, n (%) 15 (27%)
Grade ≥3 PN at last follow-up 0

Study details

NICE has recommended ADCETRIS as a cost-effective option for treating adult CD30+ patients with R/R HL post-ASCT

Professor Radford explains the approved funding for these patients:

“It is a great relief for patients and their doctors that we will continue to have access to ADCETRIS for relapsed or refractory Hodgkin lymphoma. This medicine has become the backbone of treatment following recurrence of disease after ASCT and has transformed outcomes for these patients since it became available in the UK in 2012.”

Treatment of relapsed or refractory (R/R) Hodgkin lymphoma (HL) patients post-ASCT with brentuximab vedotin

Treatment of relapsed or refractory

Dr Stephen Robinson

Consultant in Haematology, Bristol

Haematology and Oncology Centre

Watch presentation

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.